LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro

/in , /by

Michael M. Poon, Alexander R. Broadhead, Christopher S. Baccei, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Lino Valdez, Yifeng Xiong, Austin C. Chen, Timothy R. Watkins, Daniel S. Lorrain

Presented at ATS 2026

PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects

/in , /by

Daniel S. Lorrain, Michael M. Poon, Kym I. Lorrain, Alexander R. Broadhead, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Austin C. Chen

Presented at ATS 2026

The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)

/in , /by

Geraldine C Edu, Karin J Stebbins, Alexander R Broadhead, Michael M Poon, Ariana O Lorenzana, Thomas Schrader, Yifeng Xiong, Jill Baccei, Ari J Green, Jonah R Chan, and Daniel S Lorrain

Presented at Neuroscience 2019

Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen & Daniel S. Lorrain

Scientific Reports

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

/in , /by

Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana J. Lorenzana, Jeffrey R. Roppe, Jill M. Baccei, Christopher S. Baccei, Austin C. Chen, Ari J. Green, Daniel S. Lorrain, and Jonah R. Chan

PNAS

Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques

/in , /by

Aldric Hama, Karin Stebbins, Chris Baccei, Daniel Lorrain, Austin Chen, Takahiro Natsume, Hiroryuki Takamatsu

Presented at IASP 2024 World Congress on Pain

The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis

/in , /by

Michael Poon, Kym Lorrain, Alexander Broadhead, Karin Stebbins, Didier Bagnol, Geraldine Edu, Gregory Joseph, Christopher Baccei, Jeffrey Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel Lorrain

Respiratory Research

CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis

/in , /by

A. R. Broadhead, C. S. Baccei, D. Bagnol, K. I. Lorrain, G. C. Edu, M. M. Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, Y. Xiong, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression

/in , /by

D. Bagnol, A. R. Broadhead, C. S. Baccei, K. I. Lorrain, G. C. Edu, K. Stebbins, M. M.
Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

LPA-Induced Activation of Satellite Glial Cells and Its Modulation by PIPE-791, a novel LPA1 antagonist, in an In Vitro Pain Model

/in , /by

K.I. Lorrain, A. R. Broadhead, D. Bagnol, M. M. Poon, G. Joseph, J.R. Roppe, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

©2026 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin